Abstract
The FDA granted accelerated approval to selinexor plus low-dose dexamethasone for triple-class refractory multiple myeloma, despite an advisory panel's concerns about the drug's toxicity and the lack of randomized clinical data.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have